Varivax Dosage Guide - - varivax adult


varivax adult - VARIVAX® (Varicella Virus Vaccine Live) | Official Site

VARIVAX is contraindicated for use in pregnant women because the vaccine contains live, attenuated varicella virus, and it is known that wild-type varicella virus, if acquired during pregnancy, can cause congenital varicella. It is not known whether varicella vaccine virus is excreted in human milk. Vaccination is the best way to prevent chickenpox. A chickenpox vaccine has been available in the U.S. since 1995 and is easy to get from a doctor or a public health clinic. The chickenpox vaccine Author: Florence Byrd.

Oct 15, 2018 · Adolescents and Adults. Adolescents and adults 13 years of age and older should receive a 0.5-mL dose administered subcutaneously at elected date and a second 0.5-mL dose 4 to 8 weeks later. VARIVAX is for subcutaneous administration. The outer aspect of the upper arm (deltoid) is the preferred site of injection.Drug class: viral vaccines. Nov 27, 2007 · The varicella vaccine: 4 things you should know. All children should now receive 2 doses of varicella vaccine. The timing of the first and second dose should correspond with the administration of the MMR vaccine. Children older than 6 years of age and adults who previously received only 1 dose of vaccine should receive 1 more dose.

• Do not give varicella vaccine to a person receiving high-dose systemic immunosuppressive therapy (e.g., two weeks or more of daily receipt of 20 mg or more [or 2 mg/kg body weight or more] of prednisone or equivalent) • Do not give varicella vaccine to an adult or adolescent with CD4+ T-lymphocytes count. Adolescents (13 Years of Age and Older) and Adults. In clinical trials involving healthy adolescents and adults, the majority of whom received two doses of VARIVAX and were monitored for up to 42 days after any dose, the frequencies of fever, injection-site complaints, or rashes are shown in Table 2.

Oct 01, 2018 · Although no placebo-controlled trial was carried out in adolescents and adults, the protective efficacy of Varivax was determined by evaluation of protection when vaccinees received 2 doses of Varivax 4 or 8 weeks apart and were subsequently exposed to chickenpox in a household setting. Among the subset of vaccinees who were actively followed Drug class: viral vaccines.